Amazon Prime Video Launches New Features for Thursday Night Football Allowing NFL Fans Around the Globe to Customize Their Streaming Experience
(NASDAQ: AMZN) — For the third straight year, Amazon Prime Video brings NFL fans around the world Thursday Night Football Presented by Bud Light Platinum and launches new innovations allowing Prime members to experience the game they love like never before, with a new lineup of expert insight and analysis, access to robust live data and a simplified experience.
“We’re revolutionizing the way football fans stream Thursday Night Football and allowing Prime members to personalize how they watch and hear the game,” said Marie Donoghue, Vice President of Prime Video Sports. “There’s something for every football fan — from deeper gameplay analytics at their fingertips, to differentiated commentary, to the ability to easily discover and watch on any device, anywhere in the world. We think both longtime sports fans and those new to the game will love watching and engaging with TNF on Prime Video and Twitch.”
The Thursday Night Football schedule on Amazon Prime Video and Twitch kicks off Thursday, September 26 at 8:20 PM Eastern with the Green Bay Packers hosting the Philadelphia Eagles.
X-Ray Puts Fans in Control
X-Ray for TNF creates opportunities for fans to watch and understand the game without taking their eyes off the screen or missing a play. This season, X-Ray brings some of the same Next Gen Stats previously available only to coaches and announcers to all TNF fans on demand, on every play and at their fingertips, driving a deeper appreciation for the on field action. Fans can dive into leading edge insights like a quarterback’s average time to throw, a running back’s average yards after contact and a wide receiver’s average yards of separation, which are enabled through Next Gen Stats’ real-time player tracking.
X-Ray is available for football fans streaming TNF on Android, iOS, and Fire TV. Prime Video is also enabling analytics on the go with a discoverable and easy to use mobile experience that allows customers to bring up and dismiss real-time stats by simply flipping their phones. To access X-Ray, fans can simply flip their phones, tap the “Stats by X-Ray” button on their phone or tablet or click ‘up’ on the Fire TV remote control during the game.
A Different Kind of NFL Show
NFL Next, a new 30-minute live show available exclusively on Prime Video at 7:00 PM Eastern each Thursday and produced by NFL Films, will provide viewers with fresh insight and smart commentary from two-time Super Bowl Champion Chris Long, NFL Network’s Kay Adams and Next Gen Stats expert James Koh. NFL Next will host featured guests including current and former players, while iconic sports journalists Hannah Storm and Andrea Kremer will return to provide commentary, in addition to leading play-by-play and analysis.
“We’re excited to collaborate once again with Amazon Prime Video to produce a different kind of NFL show,” said Ross Ketover, Chief Executive of NFL Films. “To have the talents of Chris Long, one of the most insightful players to play this game, paired with a dynamic personality like Kay Adams makes for a show we think fans are going to love.”
“I am excited to be part of NFL Next and the Amazon family,” said Chris Long. “It was important to me that my first venture into football broadcasting was in a forum that I feel will give the viewer a unique under the hood look of the game.”
Choose Your Audio
Prime Video is once again producing multiple audio options to enable football fans around the world to customize their viewing experience. In addition to the default FOX broadcast with Joe Buck and Troy Aikman, Prime members can choose from two additional Prime Video exclusive audio streams: Hannah Storm and Andrea Kremer and U.K. English language broadcasters Derek Rae and Tommy Smyth.
“I can’t wait for another season of Thursday Night Football!” said Hannah Storm. “It’s such a challenging and fun opportunity and we have an awesome group of women in front of the mic and behind the scenes to give Prime members our own unique perspective on the game.”
“I’m thrilled that Hannah and I are building on our groundbreaking first season coupled with our expanding roles on NFL Next as well as offering the most unique viewing experience with Amazon’s technical innovations,” said Andrea Kremer.
FOX Deportes Spanish Production
Additionally, Prime members in the US and Mexico have access to FOX Deportes, the exclusive Spanish-language broadcast.
Join the Twitch Party
For the third year, TNF will also be available to Twitch viewers, including co-streamed commentary from popular streamers on Twitch’s interactive social video service, so get ready to fill chat with your finest cheers, memes, and emotes. Many of your favorite streamers will be co-streaming the matchups and adding their unique commentary to the broadcasts, including surprise guests coming later this season. Fans can cheer on their favorite teams with NFL themed emotes and test their fandom with real-time game trivia all season long. Check out the Twitch blog post to see a complete list of co-streamers for every week. Visit Prime Video to view the full TNF schedule and watch the official FOX broadcast available in over 200 countries and territories around the world.
The TNF games scheduled to air on FOX, NFL Network and Amazon Prime Video kick off Thursday, September 26 at 8:20 PM Eastern with the Green Bay Packers hosting the Philadelphia Eagles. TNF games will be available to stream on Amazon via Prime Video and Twitch in addition to NFL, FOX and FOX Deportes digital properties across devices. NFL Network and Amazon availability subject to change.
About Prime Video
Prime Video is a premium streaming service that offers customers a vast collection of digital videos — all with the ease of finding what they love to watch in one place.
- Included with Prime: Watch thousands of popular movies and TV shows, including our critically-acclaimed Amazon Originals including the Emmy Award-winning The Marvelous Mrs. Maisel, Tom Clancy’s Jack Ryan, The Boys, Homecoming, Hanna, Fleabag, Good Omens, Carnival Row, Mindy Kaling’s Late Night, Donald Glover’s Guava Island, the Academy Award-winning Manchester by the Sea and The Salesman, Academy Award-nominated The Big Sick and Cold War, and exclusives, live sports including Thursday Night Football and licensed and self-published content available in more than 200 countries and territories worldwide.
- Watch more with Prime Video Channels: Prime members can add 150+ channels in the US like HBO, Cinemax, STARZ, SHOWTIME, CBS All Access, NBA League Pass and MLB.tv — no extra apps to download, and no cable required. Only pay for the ones you want, and cancel anytime. View the full list of channels available at amazon.com/channels.
- Rent or Buy: Enjoy hundreds of thousands of titles, including new-release movies and entire seasons of current TV episodes, available for all Amazon customers to rent or buy.
- Instant access: Watch where and when you want with the Prime Video app on your smart TV, mobile device, Fire TV, Fire tablet, Apple TV, Chromecast, game consoles, Comcast X1 or from the web. For a complete list of compatible devices, visit amazon.com/howtostream.
- Enhanced experiences: Make the most of every viewing with 4K Ultra HD- and High Dynamic Range (HDR)-compatible content. Go behind the scenes of your favorite movies and TV shows with exclusive X-Ray access, powered by IMDb. Save it for later with select mobile downloads for offline viewing.
In addition to access to movies and TV shows included with Prime, the Prime membership includes unlimited fast free shipping options across all categories available on Amazon, more than two million songs and thousands of playlists and stations with Prime Music, secure photo storage with Prime Photos, unlimited reading with Prime Reading, unlimited access to a digital audiobook catalogue with Audible Channels for Prime, a rotating selection of free digital games and in-game loot with Twitch Prime, early access to select Lightning Deals, exclusive access and discounts to select items, and more. To sign up for Prime or to find out more visit: amazon.com/prime.
About Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190925005313/en/
Contact information
Amazon.com, Inc.
Media Hotline
Amazon-pr@amazon.com
www.amazon.com/pr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom